UPDATE: JPMorgan Downgrades Nektar Therapeutics (NKTR) to Underweight
Tweet Send to a Friend
(Updated - August 8, 2022 4:27 AM EDT)
JPMorgan analyst Jessica Fye downgraded Nektar Therapeutics (NASDAQ: NKTR) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
JPMorgan analyst Jessica Fye downgraded Nektar Therapeutics (NASDAQ: NKTR) from Neutral ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
